LoQus23 Therapeutics

LoQus23 Therapeutics is a biotechnology company developing small molecule drugs to stop DNA instability and slow neurodegeneration in Huntington's Disease and similar triplet repeat expansion diseases. Their lead program targets MutSβ, aiming to provide a potentially disease-modifying therapy. The company utilizes a structure-based approach to design small molecule drugs for convenient administration.

Buy Funded Startups lists

Funding Round: Series A

Funding Amount: $43M

Date: 02-Oct-2024

Investors: Forbion, SV Health Investors' Dementia Discovery Fund (DDF), Novartis Venture Fund (NVF)

Markets: Biotechnology, Pharmaceuticals, HealthTech, Life Sciences

HQ: Cambridge, Cambridgeshire, United Kingdom

Founded: 2019

Website: https://www.loqus23.com/

LinkedIn: https://www.linkedin.com/company/loqus23-therapeutics-ltd

Twitter: https://twitter.com/loqus23

Instagram: